Hybio Pharmaceutical Co., Ltd. (SHE:300199)
China
· Delayed Price · Currency is CNY 16.25
-0.03 (-0.18%)
Jun 27, 2025, 3:04 PM CST
Hybio Pharmaceutical Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | -89.68 | -173.65 | -513.88 | -370.55 | 30.81 | -609.43 | Upgrade
|
Depreciation & Amortization | 146.75 | 146.75 | 155.54 | 140.59 | 135.78 | 104.54 | Upgrade
|
Other Amortization | 4.16 | 4.16 | 4.9 | 3.89 | 3.7 | 4.14 | Upgrade
|
Loss (Gain) From Sale of Assets | -42.78 | -42.78 | 0.51 | -3.41 | -35.2 | 0.95 | Upgrade
|
Asset Writedown & Restructuring Costs | 82.43 | 82.43 | 99.94 | 23.05 | 75.31 | 10.86 | Upgrade
|
Loss (Gain) From Sale of Investments | -1.55 | -1.55 | -43.83 | 86.06 | -372.29 | -8.51 | Upgrade
|
Provision & Write-off of Bad Debts | 5.55 | 5.55 | 2.96 | 35.95 | 70.22 | 424.52 | Upgrade
|
Other Operating Activities | 77.4 | 136.1 | 166.02 | 142.83 | 127.31 | 78.19 | Upgrade
|
Change in Accounts Receivable | 26.37 | 26.37 | 121.2 | -60.54 | 17.56 | 136.3 | Upgrade
|
Change in Inventory | -80.07 | -80.07 | 20.98 | -57.7 | 19.28 | -42.37 | Upgrade
|
Change in Accounts Payable | 78.32 | 78.32 | -17.12 | 59.6 | 81 | -65.12 | Upgrade
|
Change in Other Net Operating Assets | -16.53 | -16.53 | -0.03 | 16.56 | - | - | Upgrade
|
Operating Cash Flow | 189.98 | 164.71 | -3.54 | 15.81 | 156.83 | 47.99 | Upgrade
|
Operating Cash Flow Growth | 286.80% | - | - | -89.92% | 226.79% | -54.14% | Upgrade
|
Capital Expenditures | -132.22 | -115.84 | -81.76 | -189.85 | -199 | -243.66 | Upgrade
|
Sale of Property, Plant & Equipment | 45.28 | 45.53 | 1.07 | 47.49 | 0.14 | 0.06 | Upgrade
|
Cash Acquisitions | - | - | - | -0.1 | -3.92 | - | Upgrade
|
Divestitures | - | - | - | -1.93 | - | - | Upgrade
|
Investment in Securities | 3.42 | 0.3 | 228.37 | 195.29 | 21.2 | -15 | Upgrade
|
Other Investing Activities | -0.61 | - | 0.03 | 0.82 | 3.19 | 0.14 | Upgrade
|
Investing Cash Flow | -84.13 | -70.01 | 147.71 | 51.72 | -178.39 | -258.47 | Upgrade
|
Short-Term Debt Issued | - | 190.4 | 12 | 5 | - | - | Upgrade
|
Long-Term Debt Issued | - | 1,339 | 1,378 | 537.29 | 1,457 | 641.67 | Upgrade
|
Total Debt Issued | 1,397 | 1,529 | 1,390 | 542.29 | 1,457 | 641.67 | Upgrade
|
Short-Term Debt Repaid | - | -207.4 | - | - | - | - | Upgrade
|
Long-Term Debt Repaid | - | -1,546 | -1,173 | -495.09 | -1,644 | -725.87 | Upgrade
|
Total Debt Repaid | -1,331 | -1,753 | -1,173 | -495.09 | -1,644 | -725.87 | Upgrade
|
Net Debt Issued (Repaid) | 65.67 | -224.15 | 216.25 | 47.2 | -187.81 | -84.21 | Upgrade
|
Issuance of Common Stock | 2.14 | 2.14 | - | - | - | 45.05 | Upgrade
|
Common Dividends Paid | -103.51 | -111.75 | -117.9 | -114.8 | -115.64 | -104.96 | Upgrade
|
Other Financing Activities | -60.85 | -11.73 | -2.5 | -3.5 | 49.79 | 72.43 | Upgrade
|
Financing Cash Flow | -96.55 | -345.48 | 95.85 | -71.11 | -253.67 | -71.68 | Upgrade
|
Foreign Exchange Rate Adjustments | 4.56 | 3.38 | 0.92 | 2.07 | -1.58 | 1.93 | Upgrade
|
Net Cash Flow | 13.85 | -247.4 | 240.94 | -1.51 | -276.81 | -280.22 | Upgrade
|
Free Cash Flow | 57.76 | 48.87 | -85.3 | -174.04 | -42.17 | -195.67 | Upgrade
|
Free Cash Flow Margin | 7.70% | 8.28% | -19.77% | -24.71% | -5.73% | -27.11% | Upgrade
|
Free Cash Flow Per Share | 0.06 | 0.06 | -0.10 | -0.20 | -0.04 | -0.21 | Upgrade
|
Cash Income Tax Paid | 3.31 | 7.42 | 59.68 | 41.6 | 65.12 | 56.25 | Upgrade
|
Levered Free Cash Flow | -9.76 | 59.65 | -54.53 | -176.94 | -190.2 | -113.19 | Upgrade
|
Unlevered Free Cash Flow | 56.23 | 126.21 | 20.76 | -112.4 | -135.25 | -76.16 | Upgrade
|
Change in Net Working Capital | -27.14 | -127.92 | -173.66 | -29.55 | -93.19 | -399.6 | Upgrade
|
Updated Oct 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.